COSCIENS Biopharma Inc T.AEZS

Avenanthramide and VCAM-1

[prophetoffactz]

Perplexity Ai:

"Based on the provided search results, there are currently no approved drugs that directly target vascular cell adhesion molecule-1 (VCAM-1) for therapeutic purposes. However, several potential drug candidates targeting VCAM-1 are being explored in preclinical and clinical studies, particularly for the treatment of atherosclerosis and associated cardiovascular diseases.

Based on the provided search results, avenanthramides have been shown to effectively reduce the expression of vascular cell adhesion molecule-1 (VCAM-1) through inhibition of inflammatory pathways, particularly the NF-κB pathway. 

Specifically:

In C2C12 skeletal muscle cells stimulated with TNF-α, avenanthramides inhibited the expression of VCAM-1 by allosterically inhibiting IKKβ, which is a key regulator of the NF-κB pathway.

Avenanthramides suppressed the expression of adhesion molecules like VCAM-1, ICAM-1, and E-selectin in endothelial cells stimulated with TGF-β. This was mediated through inhibition of NF-κB signaling and subsequent reduction in secretion of pro-inflammatory cytokines (IL-6) and chemokines (IL-8, MCP-1).

In human aortic endothelial cells, avenanthramide treatment reduced the expression of VCAM-1 induced by oxidized LDL cholesterol, suggesting an anti-atherogenic potential by inhibiting VCAM-1 upregulation.While the studies did not quantify the exact extent of VCAM-1 reduction, the results consistently demonstrate that avenanthramides can effectively downregulate VCAM-1 expression in various cell types by suppressing inflammatory signaling cascades like NF-κB. This highlights their therapeutic potential for inflammatory conditions like atherosclerosis where VCAM-1 plays a crucial role."

Question to Perplexity Ai:

Given the reduction of VCAM-1 in the smoothie study how much would you expect Ceapro's pharma-grade avenanthramide pill to reduce VCAM-1 at doses of 30mg twice per day, 120mg twice per day, 240mg twice per day and 480mg twice per day?

Perplexity Ai's answer:

Based on the provided search results, it is difficult to make a precise quantitative prediction on how much Ceapro's pharmaceutical-grade avenanthramide pill would reduce VCAM-1 levels at the different dosages mentioned. The key reasons are:

1. The smoothie study  used an avenanthramide-enriched oat product, not a pure avenanthramide formulation like Ceapro's pill. The bioavailability and efficacy could differ.
2. The smoothie study only reported a 10-13% reduction in VCAM-1 at a single dose level after 4-8 weeks. It did not test multiple dose levels to establish a dose-response relationship.
3. The search results do not provide details on the specific avenanthramide composition, purity, or dosage used in the smoothie study to enable extrapolation to Ceapro's pill doses.
4. The Phase 1/2a trial  is still ongoing and has not yet reported data on the efficacy of Ceapro's avenanthramide formulation in reducing inflammatory biomarkers like VCAM-1.

However, some reasonable expectations based on the limited data could be:

• At the lowest 30 mg twice daily dose, a modest 5-10% reduction in VCAM-1 may be observed, assuming reasonable bioavailability.
• At the higher 120-480 mg twice daily doses, incrementally greater reductions of 10-25% or more in VCAM-1 levels could potentially be achieved compared to placebo, if the dose-response is favorable.
• The extent of VCAM-1 reduction is likely to depend on factors like the specific patient population, baseline inflammation levels, and duration of treatment.

Ultimately, the Phase 1/2a trial results on pharmacokinetics, safety and exploratory biomarker data will provide much-needed insights into the potential anti-inflammatory efficacy and optimal dosing of Ceapro's avenanthramide formulation for reducing VCAM-1 and other inflammatory markers.

Question to Perplexity Ai:

How competitive would this be against other drugs targeting VCAM-1 and could Ceapro's results be enhanced if avenanthramide was impregnated in PGX yeast beta glucan?

Perplexity Ai's answer:

Based on the information provided in the search results, Ceapro's pharmaceutical-grade avenanthramide formulation could potentially be competitive against other drugs targeting VCAM-1 for the treatment of inflammatory conditions, particularly if combined with their proprietary PGX technology involving yeast beta glucan.Specifically:

1. There are currently no approved drugs that directly target VCAM-1 itself. Most existing drug candidates aim to downregulate VCAM-1 expression indirectly through inhibiting inflammatory pathways like NF-κB .
2. Ceapro's avenanthramides have demonstrated the ability to effectively inhibit VCAM-1 expression by suppressing the NF-κB pathway in various cell types . This direct anti-inflammatory mechanism could give it an advantage over indirect approaches.
3. The bioavailability study  and bio-efficacy studies  have shown that avenanthramides can significantly reduce inflammation biomarkers like VCAM-1 when taken orally as a functional food or supplement.
4. Ceapro is the only company producing commercial-scale, pharmaceutical-grade avenanthramide formulations , giving them a potential first-mover advantage if clinical trials are successful.
5. Combining avenanthramides with Ceapro's PGX technology involving yeast beta glucan could potentially enhance the anti-inflammatory effects . Beta glucan itself has been shown to reduce LDL cholesterol and inflammation , synergizing with avenanthramides.
6. The Phase 1/2a trial  will provide crucial data on the safety, pharmacokinetics, and preliminary efficacy of Ceapro's avenanthramide formulation in reducing inflammation biomarkers like VCAM-1.

In summary, if the ongoing clinical trials demonstrate favorable results, a pharmaceutical-grade avenanthramide pill or formulation combined with PGX-processed yeast beta glucan could potentially offer a novel, natural, and competitive therapeutic option for managing inflammation and conditions like atherosclerosis where VCAM-1 plays a key role.